Related references
Note: Only part of the references are listed.A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
Ranjan Upadhyay et al.
CANCER DISCOVERY (2021)
Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence
Fatima Ahmetlic et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
CD4 T Cell-Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair-Deficient Tumors
Giovanni Germano et al.
CANCER DISCOVERY (2021)
Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer
Amelie Cachot et al.
SCIENCE ADVANCES (2021)
Immune evasion in HPV-head and neck precancer-cancer transition is driven by an aneuploid switch involving chromosome 9p loss
William N. William Jr et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect
Erez N. Baruch et al.
CANCER IMMUNOLOGY RESEARCH (2021)
Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma
Giacomo Oliveira et al.
NATURE (2021)
Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti-PD-1 therapy
Yeon Joo Kim et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Genetic models of human and mouse dendritic cell development and function
David A. Anderson et al.
NATURE REVIEWS IMMUNOLOGY (2021)
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inibitor Response
Meagan Montesion et al.
CANCER DISCOVERY (2021)
Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma
Shelly Kalaora et al.
NATURE COMMUNICATIONS (2020)
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
Jenny H. Lee et al.
NATURE COMMUNICATIONS (2020)
Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours
Ellen Brenner et al.
NATURE COMMUNICATIONS (2020)
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade
Davis Y. Torrejon et al.
CANCER DISCOVERY (2020)
NK cells mediate clearance of CD8(+) T cell-resistant tumors in response to STING agonists
Christopher J. Nicolai et al.
SCIENCE IMMUNOLOGY (2020)
Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer
David Y. Oh et al.
CELL (2020)
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S. Grasso et al.
CANCER CELL (2020)
cDC1 prime and are licensed by CD4+T cells to induce anti-tumour immunity
Stephen T. Ferris et al.
NATURE (2020)
Pegylated Engineered IL2 plus Anti-PD-1 Monoclonal Antibody: The Nectar Comes from the Combination
Mathieu Rouanne et al.
CANCER DISCOVERY (2020)
Functional genomic landscape of cancer-intrinsic evasion of killing by T cells
Keith A. Lawson et al.
NATURE (2020)
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors
Ivan Marquez-Rodas et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma
Anusha Kalbasi et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma
Joji Nagasaki et al.
BLOOD ADVANCES (2020)
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
Elisabeth Perez-Ruiz et al.
DRUG RESISTANCE UPDATES (2020)
Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair-Deficient Endometrial Cancer
Doga C. Gulhan et al.
JCO PRECISION ONCOLOGY (2020)
Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFN-γ
Mirjam E. Hoekstra et al.
NATURE CANCER (2020)
Bystander IFN-γ activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment
Ronan Thibaut et al.
NATURE CANCER (2020)
RIG-I-like receptors: their regulation and roles in RNA sensing
Jan Rehwinkel et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity
Elise Alspach et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2019)
Neoantigen-directed immune escape in lung cancer evolution
Rachel Rosenthal et al.
NATURE (2019)
Contact-Dependent Killing by Cytotoxic T Lymphocytes Is Insufficient for EL4 Tumor Regression In Vivo
Richard J. Beck et al.
CANCER RESEARCH (2019)
CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
Weimin Wang et al.
NATURE (2019)
β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma
Marina Ruiz de Galarreta et al.
CANCER DISCOVERY (2019)
Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer
Carino Gurjao et al.
CANCER IMMUNOLOGY RESEARCH (2019)
An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer
Marian L. Burr et al.
CANCER CELL (2019)
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2019)
Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression
Barry A. Kriegsman et al.
JOURNAL OF IMMUNOLOGY (2019)
Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
Diego Chowell et al.
NATURE MEDICINE (2019)
WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Jason J. Luke et al.
CLINICAL CANCER RESEARCH (2019)
Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade
Jeffrey J. Ishizuka et al.
NATURE (2019)
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu et al.
NATURE MEDICINE (2019)
Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance
Susanne Horn et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell et al.
SCIENCE (2018)
Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance
Susanne Horn et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses
Natalia Aptsiauri et al.
CURRENT OPINION IN IMMUNOLOGY (2018)
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
John M. Wrangle et al.
LANCET ONCOLOGY (2018)
A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing
Deng Pan et al.
SCIENCE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
Scott J. Rodig et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Genetic Mechanisms of Immune Evasion in Colorectal Cancer
Catherine S. Grasso et al.
CANCER DISCOVERY (2018)
High response rate to PD-1 blockade in desmoplastic melanomas
Zeynep Eroglu et al.
NATURE (2018)
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
Antoni Ribas et al.
CANCER DISCOVERY (2018)
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
Pascale Andre et al.
CELL (2018)
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Livnat Jerby-Arnon et al.
CELL (2018)
Tumor immune evasion arises through loss of TNF sensitivity
Conor J. Kearney et al.
SCIENCE IMMUNOLOGY (2018)
The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration
Francisco Perea et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Identification of essential genes for cancer immunotherapy
Shashank J. Patel et al.
NATURE (2017)
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Robert T. Manguso et al.
NATURE (2017)
Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
Teresa Davoli et al.
SCIENCE (2017)
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
Whijae Roh et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
Antje Sucker et al.
NATURE COMMUNICATIONS (2017)
IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting
Kazuyoshi Takeda et al.
NATURE COMMUNICATIONS (2017)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman et al.
NATURE COMMUNICATIONS (2017)
Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells
Yuying Liu et al.
NATURE COMMUNICATIONS (2017)
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott Gettinger et al.
CANCER DISCOVERY (2017)
HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model
Barbara Schroers et al.
ONCOTARGET (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy
A. R. Sanchez-Paulete et al.
ANNALS OF ONCOLOGY (2017)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
Nicholas McGranahan et al.
CELL (2017)
Broad and Conserved Immune Regulation by Genetically Heterogeneous Melanoma Cells
Natalie J. Neubert et al.
CANCER RESEARCH (2017)
Targeting NK-cell checkpoints for cancer immunotherapy
Aura Muntasell et al.
CURRENT OPINION IN IMMUNOLOGY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Alfonso R. Sanchez-Paulete et al.
CANCER DISCOVERY (2016)
Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency
Fang Zhao et al.
CANCER RESEARCH (2016)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2016)
Preventing tumor escape by targeting a post-proteasomal trimming independent epitope
Ana Textor et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
Douglas B. Johnson et al.
NATURE COMMUNICATIONS (2016)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest
Nicolas Acquavella et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Cytotoxic T Lymphocytes Block Tumor Growth Both by Lytic Activity and IFNγ-Dependent Cell-Cycle Arrest
Hirokazu Matsushita et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression
Antje Sucker et al.
CLINICAL CANCER RESEARCH (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
New insights into cancer immunoediting and its three component phases elimination, equilibrium and escape
Deepak Mittal et al.
CURRENT OPINION IN IMMUNOLOGY (2014)
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Seng-Ryong Woo et al.
IMMUNITY (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
Tobias Bald et al.
CANCER DISCOVERY (2014)
EZH2-Mediated Inactivation of IFN-γ-JAK-STAT1 Signaling Is an Effective Therapeutic Target in MYC-Driven Prostate Cancer
Zhen Ning Wee et al.
CELL REPORTS (2014)
T-helper-1-cell cytokines drive cancer into senescence
Heidi Braumueller et al.
NATURE (2013)
Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes
Monica Bernal et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Cytotoxic immunological synapses do not restrict the action of interferon-γ to antigenic target cells
Nicholas Stephen Rennie Sanderson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
NF-κB Protects Cells from Gamma Interferon-Induced RIP1-Dependent Necroptosis
Roshan J. Thapa et al.
MOLECULAR AND CELLULAR BIOLOGY (2011)
TNFR1 signaling and IFN-γ signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis
Nele Mueller-Hermelink et al.
CANCER CELL (2008)
Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival
David S. Alberts et al.
GYNECOLOGIC ONCOLOGY (2008)
Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-γ
JA Gollob et al.
CANCER RESEARCH (2005)
Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma
SE Al-Batran et al.
CANCER RESEARCH (2005)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Share Paper
